<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889068</url>
  </required_header>
  <id_info>
    <org_study_id>PSS2014/NGSDI-BONNET/NK</org_study_id>
    <nct_id>NCT02889068</nct_id>
  </id_info>
  <brief_title>Targeted Next Generation Sequencing and Intellectual Disability</brief_title>
  <acronym>NGS-DI</acronym>
  <official_title>Targeted Next Generation Sequencing and Intellectual Disability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes&#xD;
      involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In&#xD;
      other words, it concerns the number of patients whose etiologic diagnosis will be established&#xD;
      with NGS and could not with common techniques. Actually, the molecular etiology of&#xD;
      intellectual disability is crucial to calculate the risk of recurrence and allows the&#xD;
      perinatal diagnosis to these families.&#xD;
&#xD;
      Secondary purposes are:&#xD;
&#xD;
        1. To determine the place of NGS in the strategy of etiologic diagnosis of intellectual&#xD;
           disability, to determine the order of analyses performed for a patient with intellectual&#xD;
           disability without clinical signs.&#xD;
&#xD;
        2. To evaluate the number of variants with unknown significance and thus non-usable for&#xD;
           genetic counselling without supplementary analysis.&#xD;
&#xD;
        3. To determine the number of samples that can be at most pooled keeping a good efficacy of&#xD;
           capture and results with suitable read depth&#xD;
&#xD;
        4. To determine the possibility of detecting copy number variations (CNVs) in genes of&#xD;
           interest with NGS&#xD;
&#xD;
        5. To establish genotype/phenotype correlations for each gene for which a mutation has been&#xD;
           identified&#xD;
&#xD;
        6. To optimize the software pipelining for a rapid analysis for diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with certain etiologic diagnosis established with NGS</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with etiologic diagnosis established with NGS or with other techniques (array-CGH)</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obtained read depth according to number of pooled samples</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with variant with unknown significance, needing supplementary analyses to prove its involvement in intellectual disability</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNVs detected with NGS or array-CGH (reference technique for CNV detection).</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical phenotype for each gene for which a causal mutation is identified by NGS</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of analysis of NGS raw data</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Intellectual Disability</condition>
  <arm_group>
    <arm_group_label>Intellectual disability</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Intellectual disability</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen DNA from blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe to moderate intellectual disability, with syndrome or not.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate or severe intellectual disability&#xD;
&#xD;
          -  Availability of patient and parent DNA&#xD;
&#xD;
          -  No etiologic diagnosis with standard approaches: negative fragile X, normal pangenomic&#xD;
             180K and 1M array-CGH&#xD;
&#xD;
          -  Informed consent of person having parental authority&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non availability of parent DNA&#xD;
&#xD;
          -  Patient lost to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline BONNET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Nancy Laboratoire de Génétique Hôpitaux de Brabois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chru Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 31, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intellectual Disability</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

